• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

Minerva Single-Arm Study


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Completed
Application Number /
Requirement Number
P140013 / PAS001
Date Original Protocol Accepted 07/27/2015
Date Current Protocol Accepted  
Study Name Minerva Single-Arm Study
Device Name MINERVA ENDOMETRIAL ABLATION SYSTEM
Clinical Trial Number(s) NCT01569763 NCT02023801 NCT02029911 NCT02035332 
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: At least 22 yrs
Detailed Study Protocol Parameters
Study Objectives The Minerva Single-Arm Study is a single-arm, non-randomized, multicenter study to evaluate the safety and effectiveness of the Minerva Endometrial Ablation System. The Post Approval Study will collect extended effectiveness and safety data at 2-3 years post treatment.
Study Population Pre-menopausal women with menorrhagia (excessive uterine bleeding) due to benign causes for whom childbearing is complete or who no longer wish to retain fertility.
Sample Size Up to 110 women
Key Study Endpoints Any treatments or hysterectomy for dysfunctional uterine bleeding
Compliance with contraception
Any pregnancies
Menstrual status (questions assess bleeding, i.e., amenorrhea, spotting hypomenorrhea, eumenorrhea or menorrhagia)
Any gynecological adverse events
Completion of Quality of Life Questionnaire
Follow-up Visits and Length of Follow-up Three years
One year (data were provided premarket), two year, and three year
Interim or Final Data Summary
Actual Number of Patients Enrolled 110 subjects
Actual Number of Sites Enrolled 7 study sites
Patient Follow-up Rate 12 month follow-up: 104/110 subjects (94.5%)
24 month follow-up: 72/101 subjects (71.3%)
36 month follow-up: 93/101 subjects (92.1%)
Final Safety Findings There were a total of 199 adverse events, including one serious adverse event (SAE) and 198 non-serious adverse events, reported at the 2-4 weeks, 3 month, 6 month, and 12 month follow-up. There was one report of pregnancy at the 12 month follow-up. There was one serious adverse event (SAE) and 11 non-serious gynecological adverse events reported at the 2- and 3-year follow-up. The one SAE was due to pelvic pain in one subject which was not determined to be device or procedure-related. There were no unanticipated device-related adverse events in the study through the 3-year follow-up
Final Effect Findings Primary effectiveness endpoint: The overall success rate based on PBLAC results was 91.8% (101/110) at 12 months.
Other effectiveness endpoints: At 12 months 80.8% of subjects responded that they observed a decrease in pre-menstrual symptoms, 54.8% observed a decrease in dysmenorrhea, 97.6% reported satisfied or very satisfied with the procedure, and 98.8% of subjects responded that they would recommend the procedure based on the Menstrual Impact Questionnaire (MIQ). At 24 months and 36 months the overall success rate (reported by blood loss assessment of eumenorrhea or less) was 92.1% and 93.1%, respectively. At 24 months and 36 months 97.2% and 98.9% of subjects reported being satisfied or very satisfied with the procedure, respectively.
Recommendations for Labeling Changes Yes, labeling change recommended to update the device labeling with the final study results.

General
Study Status Completed
Application Number /
Requirement Number
P140013 / PAS002
Date Original Protocol Accepted 07/25/2015
Date Current Protocol Accepted 07/25/2015
Study Name Minerva Pivotal Study
Device Name MINERVA ENDOMETRIAL ABLATION SYSTEM
Clinical Trial Number(s) NCT01569763 NCT02023801 NCT02029911 NCT02035332 
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: At least 22 yrs
Detailed Study Protocol Parameters
Study Objectives The Minerva Pivotal Study is a randomized (2:1), controlled, multicenter study to evaluate the safety and effectiveness of the Minerva Endometrial Ablation System. The Post Approval study will collect extended effectiveness and safety data at 2-3 years post treatment.
Study Population Pre-menopausal women with menorrhagia (excessive uterine bleeding) due to benign causes for whom childbearing is complete or who no longer wish to retain fertility.
The premarket study included a rollerball control group.
Sample Size Up to 162 women (108 treatment arm and 54 control arm)
Key Study Endpoints Any treatments or hysterectomy for dysfunctional uterine bleeding
Compliance with contraception
Any pregnancies
Menstrual status (questions assess bleeding, i.e., amenorrhea, spotting hypomenorrhea, eumenorrhea or menorrhagia)
Any gynecological adverse events
Completion of Quality of Life Questionnaire
Follow-up Visits and Length of Follow-up Three years
30 days (data were provided premarket), one year, two year, and three year
Interim or Final Data Summary
Actual Number of Patients Enrolled 153 subjects were enrolled in the study
Actual Number of Sites Enrolled 13 sites were enrolled in the study
Patient Follow-up Rate The 3-year follow-up rate was 125/153 total subjects (81.7%). This included 88/102 subjects (86.3%) in the Minerva treatment arm and 37/51 subjects (72.5%) in the Rollerball control arm.
Final Safety Findings There were no unexpected device-related adverse events in the Minerva Pivotal study. There were five events classified as Serious Adverse Events (SAEs) in the Minerva Group. The SAEs were as follows:

Four Hysterectomies were performed, two (2) for pelvic cramping, one (1) for fibroids and one (1) for chronic pelvic pain secondary to a diagnosis of hematometra.

One pregnancy was reported between the 12- and 24-month reporting period. A Dilation and Curettage (D&C) was performed to terminate the pregnancy.
Final Effect Findings Success Rate
The following success rates were reported at 1, 2, and 3 years in the intent-to-treat (ITT) population:

1 year*
Minerva (N=102): 95 (93.1%); 95% CI (86.4%, 97.2%)
Rollerball (N=51): 41 (80.4%); 95% CI (66.9%, 90.2%)

2 years**
Minerva (N=102): 89 (87.3%); 95% CI (79.2%, 93.0%)
Rollerball (N=51): 35 (68.6%); 95% CI (54.1%, 80.9%)

3 years**
Minerva (N=102): 87 (85.3%); 95% CI (76.9%, 91.5%)
Rollerball (N=51): 35 (68.6%); 95% CI (54.1%, 80.9%)

*Based on Alkaline Hematase lab value
**Based on telephone questionnaires
Amenorrhea Rate
The following amenorrhea rates were reported at 1 and 3 years in the intent-to-treat (ITT) population:

1 year
Minerva (N=102): 73 (71.6%); 95% CI (61.8%, 80.1%)
Rollerball (N=51): 25 (49.0%); 95% CI (34.8%, 63.4%)

3 years*
Minerva (N=102): 58 (56.9%); 95% CI (46.7%, 66.6%)
Rollerball (N=51): 19 (37.3%); 95% CI (24.1%, 51.9%)

*Mean follow-up time of 4.1 years

Subject Satisfaction
At 2- and 3-year follow-up, 93.4% and 95.5% of the Minerva subjects, respectively compared to 92.1% and 89.2% of the Rollerball subjects, respectively were “Satisfied” or “Very Satisfied” post-procedure. In addition, at the 2- and 3-year follow-up, 94.6% and 95.4% of the Minerva subjects, respectively compared to 94.8% and 91.9% of Rollerball subjects, respectively would “Maybe” or “Definitely” recommend the procedure to a friend or relative with a similar problem
Study Strengths & Weaknesses N/A
Recommendations for Labeling Changes Yes, labeling change recommended to update the device labeling with the final study results.




Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-